How to use the speech recognition tool?
Efficacy & Safety Study of Bilateral Intravitreal Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT).
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: Yes
- Opening Date: 2018-12-20
- Closing Date: 2024-06-01
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Neuro-Ophthalmology Rare Diseases (WG2)
This ERN is supported by: